Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Alexandria
AddedMar 19, 2024
UpdatedJun 28, 2026
Alexandria

Alexandria

Operating

Leading REIT investing in life science and tech office spaces.

Location
Pasadena, CA, US
Founded
1994
Firm
Compare
Portfolio
Fundraising
Employees

Investments

Biomilq
Biomilq

Total Raised

$24.5M

Rounds

3

Series A$21MOctober 2021
Kojin Therapeutics
Kojin Therapeutics

Total Raised

$60M

Rounds

1

Series A$60MJune 2021
Stablix
Stablix

Total Raised

$63M

Rounds

1

Series A$63MJune 2021
Think Brilliant Media Studios
Think Brilliant Media Studios

Total Raised

$12M

Rounds

2

Private Equity$7MAugust 2020
TerMir
TerMir

Total Raised

$544k

Rounds

2

Grant$100kJuly 2020
Crop Enhancement
Crop Enhancement

Total Raised

$16.5M

Rounds

4

Series B$8MApril 2020
Triplet Therapeutics
Triplet Therapeutics

Total Raised

$59M

Rounds

2

Series A$49MDecember 2019
Immunitas Therapeutics
Immunitas Therapeutics

Total Raised

$97M

Rounds

2

Series A$39MNovember 2019
Cradle Genomics
Cradle Genomics

Total Raised

$23.1M

Rounds

2

Series A$17.1MJuly 2019
Strand Therapeutics
Strand Therapeutics

Total Raised

$104.2M

Rounds

6

Seed$6MJune 2019
Vividion Therapeutics
Vividion Therapeutics
Acquired

Total Raised

$371.5M

Rounds

5

Series B$82MApril 2019
Halio
Halio

Total Raised

$399M

Rounds

11

Series D$100MJanuary 2019
Relay Therapeutics
Relay Therapeutics
Public

Total Raised

$1.2B

Rounds

7

Series C$400MDecember 2018
Series B$63MDecember 2017
KSQ Therapeutics
KSQ Therapeutics

Total Raised

$156M

Rounds

2

Series C$80MSeptember 2018
Series B$76MOctober 2017
Nohla Therapeutics
Nohla Therapeutics
Acquired

Total Raised

$120.5M

Rounds

4

Series B$11MJuly 2018
Aitia
Aitia

Total Raised

$77.3M

Rounds

10

Series Unknown$6MAugust 2017
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series A$15.6MJune 2017
Benson Hill
Benson Hill
Public

Total Raised

$592.7M

Rounds

15

Series B$25MMay 2017
GenePeeks
GenePeeks

Total Raised

$28.8M

Rounds

4

Series B$16MJanuary 2017
AgriMetis
AgriMetis

Total Raised

$32M

Rounds

3

Series B$23.5MJanuary 2017
Avidity Biosciences
Avidity Biosciences
Public

Total Raised

$347.1M

Rounds

7

Series B$16MJanuary 2017
Synthego
Synthego

Total Raised

$460.5M

Rounds

9

Series B$41MJanuary 2017
ApoGen Biotechnologies
ApoGen Biotechnologies

Total Raised

$11M

Rounds

3

Series A$7MDecember 2016